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ABSTRACT 
A double-blind randomized controlled trial was performed to compare the safety and 
efficacy of α-lipoic acid(ALA) in liver transplantation. The grafts were randomized to 
receive ALA or placebo before the cold ischemia time. Furthermore, patients 
transplanted with the ALA-perfused graft received 600mg of intravenous ALA, while 
patients with the non-perfused graft received the placebo just before graft 
reperfusion. Hepatic biopsy was performed 2 hours post-reperfusion. Blood samples 
were collected before, during and 1 and 2 days after reperfusion. qPCR analysis was 
performed on biopsies to assess genes involved in the response to hypoxia, 
apoptosis, cell growth, survival and proliferation, cytokine production and tissue 
damage protection. Nine of 40 patients developed post-reperfusion syndrome(PRS), 
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but 7 of them belonged to the control group. There was a decrease in PHD2 and an 
increase in HIF-1 and Birc2 transcript levels in the biopsies from the ALA-treated vs 
the control group of patients. Additionally, plasma levels of alarmins were lower in 
ALA-treated patients than control patients, which suggests that ALA-treated grafts 
are less inflammatory than untreated grafts. These results showed that ALA is safe 
for use in liver transplantation, induces gene changes that protect against hypoxia 
and oxidative stress and reduces the appearance of PRS. 
 
1. INTRODUCTION 
In the last decade, there has been a shortage of organs, and therefore, the use of 
non-optimal donors has increased. Livers from marginal donors show increased 
susceptibility to ischemia reperfusion injury (IRI) [1, 2]. IRI is considered a major 
cause of primary graft non-function following liver transplantation and is associated 
with high rates of morbi-mortality and a high incidence of both acute and chronic 
rejection[3]. Moreover, severe cases of IRI can lead to multiorgan failure; in this 
context, one of the major organs affected is the kidney. Another manifestation of 
hepatic IRI is post-reperfusion syndrome (PRS), which is characterized by 
hemodynamic instability after reperfusion. 
 
Liver transplantation ischemia is a type of cold ischemia, where the organ lacking 
blood flow is simultaneously cooled during ischemia. Reactive oxygen species 
(ROS) and oxidative stress are the most significant mediators of IRI[4]. The ROS 
generated by hepatocytes at the onset of IRI, in conjunction with cytokine release 
from Kupffer cells, attract neutrophils to the site of damage[5]. The immediate 
immune reaction is mediated by the production of proinflammatory cytokines and 
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chemokines, increased generation of ROS, enhanced adhesion molecule expression 
and infiltration of tissues by circulating lymphocytes and/or monocytes[5-7]. 
 
In animal models, several strategies have been assessed to protect the liver from 
IRI[8]. However, none of these strategies are currently used in humans to prevent 
the occurrence of IRI in liver transplantation. Because ROS are a central mediator in 
IRI, a putative strategy to minimize tissue damage is neutralization of ROS with the 
use of antioxidants. 
 
α-Lipoic acid (ALA) is a powerful natural antioxidant, acts both intra- and 
extracellularly and has two reduced and oxidized isomeric forms; due to these 
pharmacokinetic properties, it has a high potential for pharmacological action[9, 10]. 
The antioxidant activities of ALA include direct inactivation of ROS, regeneration of 
endogenous antioxidants (glutathione and vitamin E and C), metal-chelating activity 
(Fe2+, Cu2+ and Cd2+) and repair of tissue damage generated by oxidative stress[9-
11]. Additionally, ALA regulates the translational signals that are involved in the IRI 
process[12]. 
 
Currently, there are several preclinical studies that support the use of ALA in IRI 
models and have shown beneficial effects[13, 14]. In addition, two pilot studies 
investigating the use of ALA in IRI settings have been reported. The first study 
examined hepatic reduction, while the second one was carried out in simultaneous 
kidney-pancreas transplant patients[15, 16]. Both studies showed the beneficial 
effect of ALA.  
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Therefore, the aim of the present study was to determine the effect of ALA in 
patients undergoing liver transplantation by evaluating the several early clinical 
endpoints such as the appearance of PRS, patient survival and rejection episodes 
and changes in liver tissue transcripts, plasma alarmins and biochemical liver 
function parameters. Here, we report the results of a 2 year randomized controlled 
trial in liver transplant patients. 
 
2. MATERIALS AND METHODS 
2.1 Patients 
This is a randomized, double-blind, placebo-controlled clinical trial performed to 
evaluate the use of ALA in IRI in liver transplantation. The study included 40 liver 
transplant patients (25 men and 15 women; 59.3±10.8 years old). Transplants were 
performed between September 2015 and December 2016 at the Hospital Italiano of 
Buenos Aires, Argentina. 
 
The research activities being reported are consistent with the Principles of the 
Declarations of Helsinki and Istanbul, as outlined in the “Declaration of Istanbul on 
Organ Trafficking and Transplant Tourism.” The institutional research committee 
from Hospital Italiano approved this prospective study (n°2394) and the informed 
consent for the administration of ALA. The use of ALA is not approved in Argentina 
in liver transplantation; therefore, this study required and obtained the approval of 
the ANMAT (National Administration of Food, Technology and Medicines). 
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The recipient selection criteria were as follows: (1) aged 18 to 69 years; and (2) 
received a liver transplant. The exclusion criteria were as follows: (1) fulminant 
hepatic failure; (2) reduced liver (split and living donor); (3) liver retransplant. Donors 
were analyzed according to whether they were optimal donors or expanded criteria 
donors [ECD, non-heart beating donors, donor >65 years, sodium >155 mEq/L, 
steatosis >30%, prolonged cold ischemia time (>16 hours), prolonged warm 
ischemia time (>90 min)]. 
 
The patients received induction therapy consisting of methylprednisolone (1 g) and 
basiliximab (20 mg on days 0 and 4), and they were started on a triple 
immunosuppressive protocol (tacrolimus with a target level of 8 to 12 ng/ml, 
prednisone tapered to 4 mg/day and mycophenolate mofetil at 2 g/day). 
 
Samples of liver tissue (wedge biopsy) were obtained from the donor liver, and a 
second sample was taken from the patient 2 hours after reperfusion because 
previous studies have shown that IRI in humans becomes detectable after 30 min of 
ischemia[17]. The tissue was stored in RNAlater at -70°C for quantitative polymerase 
chain reaction (qPCR) analysis. 
 
Blood samples were obtained and biochemical parameters of liver function were 
measured before and at the end of surgery (2 hours after the unclamping procedure) 
on days 1, 2, 3, 7, and 30 after liver transplantation.  
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2.2 Experimental design 
In our previous study, with simultaneous kidney and pancreas transplant patients, we 
observed better outcomes when ALA was given to the donor and the recipient rather 
than the recipient alone. This suggested us that an early intervention with ALA, could 
be more effective to reduce the effect of IRI. However, in this study the Ethical 
Committee did not authorize to give ALA to the donors, but to the graft. Therefore, 
and in order to treat the graft as early as possible, we decided to administer ALA 
directly to the liver by portal vein, before the cold ischemia and before the graft 
reperfusion.  The justification of this regimen of treatment was based on that graft 
cold ischemia and reperfusion are noxius factors that trigger ROS. Twenty-two 
patients were recruited and preconditioned with 600 mg of ALA (in 100 ml NaCl) 
administered to the donor portal vein immediately before the cold ischemia time and 
another 600 mg of ALA 15 min prior to the reperfusion (ALA-treated group). Eighteen 
patients received placebo in identical conditions (untreated control group). The dose 
of ALA chosen for the current study was based on our previous clinical trial, that 
showed to be safe for patients and grafts [16]. 
 
The organs were flushed with 2 L of aortic flush with University of Wisconsin 
solution, and the organs were then packed and stored in ice until transplantation. 
The grafts were randomized to receive drug or placebo according to simple random 
numbers enclosed in numbered and sealed envelopes, which were opened in the 
pharmacy after the donor organ was accepted. 
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2.3 SLPI and Reg3a/PAP sandwich ELISA 
SLPI was measured by sandwich ELISAs (lower limit of detection: 0.31 ng/ml) as 
previously described[18]. Reg3/PAP was determined by sandwich ELISA following 
the manufacturer's instructions (Pancreas PAP, Dynabio, France). Absorbance was 
read in a plate reader (Rayto, China) at 450 nm with subtraction of 630 nm.  
 
2.4 qPCR analysis 
The determination of various transcripts in patient biopsies was performed through 
qPCR assays. The biopsies were kept at -70°C in RNAlater solution (Ambion, US) 
until processing. Twenty-seven biopsies were processed (13 controls and 14 of the 
ALA-treated group). Initially, mRNA purification was performed using the RNeasy 
Mini Kit (QIAGEN). A dry homogenate was generated with the biopsies using liquid 
nitrogen. This sample was resuspended in RLT Plus lysis buffer with needles of 
different caliber for better degradation. A 3 min centrifugation was performed at 
10,000 rpm. The supernatant was passed through a gDNA eliminator column (30 sec 
at 10,000 rpm). The eluate was combined with 70% ethanol, and 0.7 ml was 
transferred to the RNeasy column. After centrifugation (15 sec at 10000 rpm), the 
eluate was discarded, and the column was washed with RW1 buffer. RPE buffer was 
added to the column and washed twice (15 sec and 2 min at 10000 rpm). Dry 
centrifugation was performed to remove all possible buffer. Finally, 50 μl of RNase-
free water was added to the column and centrifuged for 1 min at 10,000 rpm, and the 
eluate was recovered. Quantification was performed using Nanodrop equipment, and 
purity was determined by analyzing the relationship between the absorbance at 260 
and 280 nm. cDNA was then obtained with an RT2 First Strand kit (QIAGEN). For 
this, 50 μl of the RNA was centrifuged for 15 sec. The gDNA elimination mixture was 
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prepared for each sample, and 700 ng of RNA was added to a final volume of 10 μl. 
The sample was centrifuged and incubated at 42°C for 5 min, immediately switched 
to ice and incubated for 1 min. The RT cocktail was prepared (according to the 
protocol). The gDNA elimination mixture was combined with 10 μl of the Cocktail RT 
and incubated for 15 min at 42°C, and the reaction was stopped by heating at 95°C 
for 5 min. Finally, 91 μl of distilled water was added. 
 
Amplification and detection of cDNA by real-time quantitative PCR was performed 
using the GoTaq® qPCR Master Mix reagent in a 96-well format on a Stratagene Mx 
3000P kit. The cycling program was as follows: 95°C for 2 min, 40 cycles at 95°C for 
15 sec and at 60°C for 45 sec. Finally, a cycle of 1 min at 95°C, 30 sec at 55°C and 
30 sec at 95°C was performed. The sequence of primers used were designed and 
assessed by the research group (Supplementary Table 1). The specificity was 
evaluated by melting curve analysis and agarose gel analysis after qPCR 
amplification. The analysis of the results was carried out by the 2-ΔΔCt method, using 
28S as the control gene. 
 
2.5 Clinical endpoints 
Several early clinical endpoints were assessed in order to evaluate the safety and 
the effect of ALA administration in liver transplantation. Among them, we determined 
the occurrence of severe PRS, rejections, graft and patient survival, the levels of 
plasma alarmins (REG3a/PAP and SLPI) and blood biochemical data that indicated 
liver and kidney function. PRS was defined as a decrease in the mean arterial 
pressure of more than 30% of the baseline value for more than one minute during 
the first five minutes after graft reperfusion. For the analysis, patients were classified 
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in two groups: i) without or with mild PRS; and ii) with severe PRS. The definition of 
mild and severe PRS was based on Hilmi et al. study [19]. Patients with mild PRS 
were those that showed a short-lived (≤ 5 minutes) of a decrease in blood pressure 
and/or heart rate less than 30% of the anhepatic levels and respond to the i.v. 
administration of 1 g CaCl2 and/or i.v. boluses of ≤ 100 µg epinephrine without 
requiring continuous infusion of vasopressor agents. On the contrary, severe PRS 
was defined as patients with persistent hypotension (more than 30% of the anhepatic 
level), asystole, or hemodynamically significant arrhythmias; patients who required a 
vasopressor infusion during the intraoperative period and infusion continued through 
the postoperative period. Other presentations of sever PRS included prolonged 
(defined as greater than 30 minutes) or recurrent (defined as reappearing within 30 
minutes after resolution) fibrinolysis that required treatment with antifibrinolytic 
agents. 
 
Furthermore, several transcripts were analyzed in liver biopsies derived from genes 
involved in the response to hypoxia (HIF-1, HIF-2, PHD1 and PHD2), apoptosis 
(Birc2), cell growth, survival and proliferation (Sestrin2, mTOR, Reg3a), cytokine 
production (IκBα) and tissue damage protection (SLPI).  
2.6 Statistical analysis 
All data are expressed as the mean ± standard deviation or median (interquartile 
range) as indicated in each figure or table. Statistical differences between 
experimental groups were calculated by GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, California, USA, 1994-1999). Mann-Whitney test, 
Wilcoxon matched-pairs signed rank test and Fisher's exact test, were used as 
indicated in each Figure and Table; p<0.05 was considered significant.  
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3. RESULTS 
Based on previous work with ALA administration in simultaneous kidney-pancreas 
transplant patients[16], we evaluated the effects of ALA administration in liver 
transplantation. For this single center placebo-controlled clinical trial, 40 patients 
were recruited and randomly divided into a control group and a group treated with 
ALA as described in the Materials and Methods. The clinical and demographic 
characteristics of the patients are shown in Table 1. There were no statistically 
significant differences between the ALA-treated and untreated groups in recipient 
and donor age and gender, Model for End-Stage Liver Disease (MELD), Child-Pugh 
score, pre-transplant serum creatinine, bilirubin, alanine aminotransferase (ALT) and 
warm and cold ischemia time. Of 40 grafts used in this study, 19 organs belonged to 
ECD; 9 and 10 in the untreated and ALA-treated group, respectively. The clinical and 
demographic characteristics of the patients´ that received ECD organs are shown in 
Table 2. For these groups of patients, there were no statistically significant 
differences between the ALA-treated and untreated groups, except for pre-transplant 
total serum bilirubin and MELD, which were higher in ALA-treated than untreated 
group of patients (Table 2). 
 
3.1 RT-qPCR analysis of liver biopsies 
To assess the impact of ALA treatment directly on the graft, we first analyzed 
mRNAs related to the response to hypoxia in liver biopsies obtained at the end of the 
reperfusion by qPCR. Figure 1 shows that ALA-treated patients had significantly 
higher and lower levels of HIF-1 and PHD2, respectively, than the untreated group, 
suggesting that the perfusion of the organ with ALA neutralizes the ROS produced 
under hypoxia and protects the liver parenchyma from further damage. However, no 
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difference was observed between the ALA-treated group and untreated group in 
other hypoxia-related genes, such as HIF-2 and PHD1 (Figure 1). The effect of the 
treatment was further analyzed by studying other transcripts related to apoptosis 
(Birc2), cell growth, survival and proliferation (Sestrin2, mTOR, Reg3a), cytokine 
production (IκBα) and tissue damage protection (SLPI). Figure 2 shows that the 
Sestrin2, mTOR, REG3a, IκBα and SLPI transcript levels were similar in both groups 
of patients. However, transcript levels of Birc2 were significantly higher in the ALA-
treated group than the control group (Figure 2). 
 
3.2 Plasma alarmin levels in liver transplant patients 
After the liver transplant, an acute stress systemic response was expected and was 
detected by measuring plasma alarmins, such as SLPI and PAP. Both proteins were 
assessed in the plasma of transplanted patients before reperfusion, during 
reperfusion and on the 1st and 2nd days after the surgery by sandwich ELISA. Figure 
3 shows that the levels of both proteins significantly increased on day 1 after surgery 
in control patients compared to the values found during reperfusion. However, the 
increase in ALA-treated patients was milder for SLPI, while REG3a/PAP was not 
changed compared to the values found in reperfusion plasma samples (Figure 3). 
Plasma sample values were quite different for each patient. Therefore, the data are 
shown compared to the values found for each patient before the surgery (Figure 3). 
 
3.3 Clinical follow up of patients 
The appearance of severe PRS was recorded during the surgery, as was described 
in Materials and Methods. Notably, 9 of 40 patients developed severe PRS, but only 
two of them belonged to the ALA-treated group (Figure 4 and Table 3). Furthermore, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
patient health was followed by monitoring the serum levels of total bilirubin, ALT and 
creatinine on the 1st, 3rd, 7th and 30th days after the surgery.  Table 4 shows that 
there was no difference between the untreated group and ALA-treated group in 
these parameters.   
 
Other variables analyzed were rejection episodes, the need for dialysis and patient 
survival. Three patients needed dialysis during the first week of transplantation in 
each group (Table 3). Severe rejection episodes were observed in 4 of 40 patients at 
30 days, but only 1 belonged to the ALA-treated group (Table 3). Three patients died 
at six months post-transplant; two from the untreated and one from ALA-treated 
group of patient (Table 3). 
 
As we mentioned above, 19 patients were transplanted with organs belonged to 
ECD. The analysis on those patients revealed that from a total of 6 patients that 
suffered PRS, 5 belonged to untreated group and only 1 to the ALA-treated group 
(Table 5). Furthermore, in this ECD group of patients, the total serum bilirubin 
measured at 30th day post-transplant was lower in ALA-treated group than untreated. 
Three patients needed dialysis in untreated and only 1 in ALA-treated patients (Table 
5). Severe rejections episodes were observed in 2 untreated and none in ALA-
treated patients at 30 days post-transplant. Furthermore, the only 1 patient that died 
within the ECD group, belonged to the untreated group (Table 5). 
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4. DISCUSION 
IRI in liver transplantation is a complex process that has an impact on short- and 
long-term graft function. One of the major factors involved in this phenomenon is the 
generation of ROS[20]. In the present clinical trial, we explored antioxidant 
therapeutic intervention to reduce early complications induce by ROS stress during 
liver transplantations. The antioxidant drug chosen was ALA, and its administration 
was done twice through the portal vein, one before cold ischemia and another before 
reperfusion. This experimental design was done in order to precondition the graft 
and alleviate ROS stress induced by cold ischemia and reperfusion injury. As main 
result, we found that ALA-treated group had a lower incidence of PRS than control 
patients.  
 
The use of ALA in a transplantation setting is not a new strategy. In a previous work 
with simultaneous kidney-pancreas transplant patients, we showed that ALA 
treatment had a positive influence on early clinical outcomes and even on mRNA 
expression of various genes in the graft biopsies. Here, we also found that 
neutralizing ROS with ALA modified the expression of several transcripts related to 
hypoxia. We observed decreased levels of PHD2, but not the PHD1 isoform, in liver 
biopsies obtained after reperfusion. These enzymes post-translationally modulate 
the activity of the α-subunit of HIF-1. The hydroxylation of HIF-1 by PHD promotes 
its degradation. As the presence of oxygen is a requirement for this activity, this 
process is suppressed in hypoxia, allowing HIF-1α to escape degradation and 
activate the transcription of target genes. In fact, in parallel to the decrease in PHD2, 
we found an increase in HIF-1 (Figure 1), which was expected. The lack of changes 
in PHD1 and HIF-2 is not a surprise since PHD1 shows a preference for HIF-2, 
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while PHD2 has a stronger substrate preference for HIF-1[21]. Furthermore, in line 
with these results, Bernhardt W. et al. determined that reduction of PHD with a PHD 
inhibitor improved short- and long-term results after allogeneic transplantation in an 
animal model[22]. 
 
In contrast to the clear effect of ALA treatment on hypoxia-related genes, we did not 
observe changes in transcripts related to cell growth, survival and proliferation 
(Sestrin2, mTOR, Reg3a), a negative regulator of the NF-κB pathway (IκBα) and 
SLPI, which has a role in wound healing. However, we observed higher levels of 
Birc-2 transcripts in biopsies from ALA-treated patients than untreated control 
patients. Since Birc2 encodes the protein c-IAP1, which is a caspase inhibitor and 
co-factor in the TNF signaling pathway[23], we hypothesized that the perfusion of the 
graft with ALA reduced the cell apoptosis in the graft. This hypothesis is supported 
by the fact that ALA-treated grafts were less likely to release alarmins, such as SLPI 
and REG3a/PAP, than control grafts, at least on the 1st day post-transplantation 
(Figure 3). On the 2nd day post-transplant, plasma levels of alarmins were similar for 
both group of patients, suggesting that the major effect of ALA is on the graft, 
probably by reducing the apoptosis and the inflammatory activity of the grafts. These 
findings are consistent with our previous work[16]. We showed that ALA treatment to 
the donor and the recipient have better short-term outcomes than those where only 
the transplant recipient was treated with ALA[16]. 
 
The relevance of the molecular and biochemical changes induced by ALA was 
observed in immediate clinical events, such as PRS. This syndrome, firstly described 
as a unique event characterized by a decrease in mean arterial pressure greater 
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than 30 % below the baseline value that last for at least 1 min and occurring during 
the first 5 min after reperfusion of the graft [24], then, it was classified by Hilmi et al 
in two groups according to the severity of the PRS[19]. The most severe event was 
named significant PRS and comprises to those patients with greater hemodynamic 
instability, a drop in mean arterial pressure and/or heart rate exceeding 30% of 
baseline, asystole or hemodynamically significant arrhythmias; or the need to start 
the infusion of vasopressors during the intraoperative period and to continue 
throughout the postoperative period. Other presentations of significant PRS included 
a prolonged (defined as lasting more than 30 min) or recurrent (defined as 
reappearing within 30 min after resolution) fibrinolysis that requires treatment with 
antifibrinolytic agents. On the contrary, those patients that presented a decrease of 
mean arterial pressure and/or heart rate that did not reach the 30% of baseline 
value, lasting for less than 5 min, and responsive to an intravenous bolus dose of 
CaCl2 (1 g) and/or epinephrine (≤ 100 µg) without the need to start a continuous 
infusion of vasopressors were classified as mild PRS. Similar to the Hilmi study, 
herein, patients with mild or no PRS were grouped together in order to compare with 
those that suffered severe PRS. Regardless the severity of the event, the incidence 
of this syndrome varies greatly between different studies, ranging from 12%[25, 26] 
to 77%[27]. In our trial we had a total of 22% severe PRS (9 patients from a total of 
40), with a rate of 39% in the untreated control group and only 9% in the ALA-treated 
group of patients. Notably, this was not related to the presence of ECD in the 
recruited patients since 50% (9 of 18) and 45% (10 of 22) of patients in the control 
and ALA-treated groups, respectively, received grafts derived from ECD. In fact, less 
PRS was observed in ECD group of patients that were treated with ALA-treatment. 
Furthermore, the 22 % of severe PRS does not seem to be related to donor age, CIT 
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and WIT since liver transplantation has been done with young donors, short CIT and 
WIT.  Several risk factors have been associated with the appearance and severity of 
PRS besides donor age, the CIT and WIT. Among them, it is recognized the 
recipient age, the Donor Risk Index, the presence of macrovescicular steatosis, the 
mismatch in size between the recipient and the grafted organ, the MELD score, the 
kidney function, the hemoglobin level, the impaired sympathetic activity and some 
aspects of the surgical technique. We do not know for sure, which of these risk 
factors influence more on the incidence of PRS in our study. However, we can 
speculate that the high recipient age could have been a relevant factor.  
 
There is a consensus about the negative impact of PRS on patient survival 
measured by intraoperative and hospital mortality. However, it is not clear if PRS 
would specifically affect the levels of liver and kidney function markers. This could be 
due to differences in the patient population recruited and the definition of PRS. In 
fact, Fukazawa et al. did not observe early graft dysfunction while Nanashima et al. 
and Chung et al. showed an early increase in bilirubin[28-30]. In our study, although 
the clear effect of ALA on the lower incidence of the PRS, this was not associated 
with lower levels of plasma bilirubin and ALT but with plasma alarmins. These facts 
appear contradictory, but it might reflect that serum alarmins levels could be better 
markers for graft and patients´ survival than bilirubin or ALT. The overall rejection 
episodes at 30 days post-transplant were very low (10%), being 16.7% in the control 
and 4.5% in the ALA-treated group of patients. If we considered patients 
transplanted with ECD, the rejection episodes were 22.2 % and 0 % in the control 
and ALA-treated group, respectively. Moreover, in these liver transplanted patients 
with ECD, we observed lower values of total serum bilirubin in ALA-treated vs 
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untreated patients at 30th day post-transplant (Table 5). This suggest that ALA 
treatment could benefit and be more relevant in liver transplant patients with ECD. 
However, this issue required further investigation.  
 
As patient death and graft rejections were low in the overall trial, it was not possible 
to definitively conclude a statistically significant effect of ALA on those parameters. 
Nevertheless, the beneficial effect of ALA on the incidence of PRS is very relevant 
considering the high perioperative mortality associated with this condition. For this 
reason, it is important to highlight the substantial difference in the incidence of PRS 
in our study between the treated group and the control group, particularly in patients 
receiving an organ from ECD (Table 5). Interestingly, by chance ALA treated group 
showed a higher MELD and bilirubin than untreated group, when the analysis was 
restricted to the ECD group (Table 2). This reinforce the idea that ALA-treatment 
could improve, at least the intraoperative clinical adverse events, even in 
unfavorable conditions.  
 
 
Some of the limitations of our studies are related to the number of patients recruited 
and the high variability observed inside each group for each of variables analyzed. 
Although a higher number of patients would be desirable, our study showed that ALA 
administration in liver transplant patients is safe and reduces the appearance of 
PRS. The safety of the drug is manifested by the lack of a higher incidence of death 
in the treated group, as well as the lack of appearance of greater metabolic 
dysfunctions or other clinical complications. Currently, a second trial will be 
undertaken to recruit more patients, mainly with ECD, confirm the beneficial clinical 
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events of the current trial and further elucidate the mechanisms of action of ALA in 
the liver biopsies.  
 
Our findings confirm the deleterious consequences of ROS as one of the major 
mechanisms responsible for graft injury in solid organ transplantation. Additionally, 
our results emphasize the necessity of an early intervention to achieve appropriate 
results, probably in the donor, before ablation. Preconditioning to reduce IRI is not a 
new concept[31, 32]. In an animal model, treatment with steroids or administration of 
the soluble ligand of P-selectin to donors with brain death increased the survival of 
the recipient compared to that of the untreated group[33]. However, it is possible that 
administration of ALA after transplantation or even at another dose could also help 
improve the outcomes. In fact, preclinical studies with animals have shown better 
results with high doses of ALA (100 mg/kg) and that lower doses (10 mg/kg), such as 
that used in our study, are less effective[34]. 
 
In general, ALA is a well-tolerated drug that may have minor side effects; however, in 
our study, these effects were not detected. The lack of intervention strategies at 
early time points in solid organ transplantation to improve short-term clinical 
outcomes, plus the safety and good results obtained with ALA, prompted us to 
propose ALA treatment as a strategy to neutralize the harmful effects of ROS 
induced by IRI. 
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FIGURE LEGENDS 
Figure 1. Relative mRNA expression of hypoxia-related genes in liver biopsies of 
transplanted patients. RT-qPCR was performed on biopsies of liver transplant 
patients from the treated and untreated patients. Data represent the median with the 
interquartile range of the relative expression of HIF-1 and 2, PHD1 and PHD2 
mRNA (- ΔCt) in the biopsies of the ALA-treated versus untreated control groups. 
*p<0.05. Mann-Whitney test. 
 
Figure 2. Relative mRNA expression of genes involved in cell growth, survival and 
proliferation, and tissue damage protection in liver biopsies of transplanted patients. 
qPCR was performed on the same biopsies as in Figure 1. Data represent the 
median with the interquartile range of the relative expression of Birc2, Sens2, mTOR, 
Reg3a, IB and SLPI of the ALA-treated versus untreated control groups. *p<0.05. 
Mann-Whitney test. 
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Figure 3. Plasma levels of SLPI and Reg3a/PAP in hepatic transplant patients. 
Plasma samples were taken before surgery, during reperfusion and on the1st and 2nd 
days after surgery. SLPI and PAP index were calculated for each patient relative to 
plasma sample values obtained before the surgery. Data represent the mean±SEM 
of the control untreated and ALA-treated groups. *p<0.05, Wilcoxon matched-pairs 
signed rank test. 
 
Figure 4. Post-reperfusion syndrome in liver transplant patients treated or without 
ALA. Post-reperfusion syndrome was defined as persistent hypotension (decrease in 
more than 30% of the anhepatic phase), asystole or arrhythmias, patients who 
required a continuous vasopressor infusion during the intra-operative period. Other 
presentations of PRS included prolonged or recurrent fibrinolysis that required 
treatment with antifibrinolytic agents.. *p<0.05, Chi-square test, two-sided. 
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Table 1. Demographic clinical data of transplanted patients1 
  
Untreated 
 n=18 
ALA-treated 
 n=22 
P = 
Recipient Age 
(years) 
61 ± 11.6 58 ± 10.3 
0.226a 
Recipient gender 
(% Male) 
61 64 
0.870b 
 
Pre-transplant serum 
creatinine (mg/dl) 
1.1 ± 0.72 1.3 ± 1.03 
0.495c 
Pre-transplant serum 
Total Bilirubin (mg/dl) 
3.8 ± 4.42 5.9 ± 6.04 
0.229c 
Pre-transplant serum 
ALT (UI/L) 
226 ±229 140 ± 198.3 
0.210c 
MELD 24 (22-25) 25 (23-29) 
0.114a 
Child Pugh 10 (5.0-12.0) 10 (6.8-12.0) 
0.749a 
CIT (h) 7 ± 1.5 7 ± 1.7 
0.678c 
WIT (min) 56 ± 7.0 67 ± 28.9 
0.117c 
Donor Age (years) 40 ± 16.7 41 ± 15.2 
0.804a 
Donor gender (% Male) 56 64 
0.604b 
1Data represent the mean ± SD for recipient and donor age, cold ischemia time 
(CIT), warm ischemia time (WIT), pre-transplant serum creatinine, total bilirubin and 
alanine transaminase (ALT); Median (interquartile range) for model for end-stage 
liver disease (MELD) and Child Pugh score; or percentage for recipient and donor 
gender. There were no statistically significant differences among the groups; aMann 
Whitney test; bChi-square; cUnpaired t test; two-tailed. 
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Table 2. Demographic and clinical data of ECD transplanted patients1 
  
Untreated 
 n=9 
ALA-treated 
 n=10 
P = 
Recipient Age 
(years) 
65 ± 4.2 60 ± 9.4 
0.458a 
Recipient gender 
(% Male) 
67 70 
0.876b 
Pre-transplant serum 
creatinine (mg/dl) 
0.9 ± 0.34 1.6 ± 1.40 
0.182 c 
Pre-transplant serum 
Total Bilirubin (mg/dl) 
1.9 ± 1.1 6.8 ± 6.32 
0.034 c 
Pre-transplant serum 
ALT (UI/L) 
176 ± 243 173 ± 214 
0.975 c 
MELD 24 (22-25) 26 (24-29) 
0.035a 
Child Pugh 7 (5.0-12.0) 9.5 (6.0-12.0) 
0.589a 
CIT (h) 7 ± 1.7 7 ± 1.4 
0.691c 
WIT (min) 55 ± 6.8 58 ± 7.9 
0.357c 
Donor Age (years) 54 ± 8.4 54 ± 7.5 
0.795a 
Donor gender (% Male) 67 50 
0.462b 
1Data represent the mean ± SD for recipient and donor age, cold ischemia time 
(CIT), warm ischemia time (WIT), pre-transplant serum creatinine, total bilirubin and 
alanine transaminase (ALT); Median (interquartile range) for model for end-stage 
liver disease (MELD) and Child Pugh score; or percentage for recipient and donor 
gender. aMann Whitney test; bChi-square; cUnpaired t test; two-tailed. 
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Table 3. Variables after surgery 
Variable  
Total 
= 40 
Untreated 
n=18 
ALA-treated 
n=22 
1P = 
Severe PRS 9 
7 
(38.9 %) 
2 
(9.0 %) 
0.025 
1st week dialysis 6 
3 
(16.7 %) 
3 
(13.6 %) 
0.790 
Rejections 
(at 1st month post-
transplant)  
4 
3 
(16.7 %) 
1 
(4.5 %) 
0.204 
Deaths (at 6th month post-
transplant) 
3 
2 
(11.1 %) 
1 
(4.5 %) 
0.433 
 
1Chi-square test, two-sided.  
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Table 4. Biochemical parameters after surgery1 
 
Day after 
surgery 
Untreated 
n=18 
ALA-treated 
n=22 
p 
C
re
a
ti
n
in
e
 (
m
g
/d
l)
 
1 1.7 ± 1.30 1.5 ± 0.64 
0.23 
2 1.5 ± 1.02 1.4 ± 0.60 
0.30 
3 1.3 ± 0.97 1.3 ± 0.75 
0.48 
7 1.0 ± 0.96 1.1 ± 0.87 
0.35 
30 1.4 ± 1.21 1.3 ± 0.46 
0.28 
T
o
ta
l 
B
il
ir
u
b
in
 (
m
g
/d
l)
 1 5.8 ± 5.75 6.2 ± 4.96 0.77 
2 4.2 ± 5.40 4.7 ± 5.03 0.75 
3 3.6 ± 3.64 4.8 ± 6.01 0.46 
7 2.4 ± 1.87 3.3 ± 5.24 0.49 
30 1.15 ± 0.63 1.2 ± 0.77 0.99 
A
L
T
 (
U
I/
L
) 
1 740 ± 988 1229 ± 1459 0.23 
2 510 ± 648 800 ± 974 0.29 
3 290 ± 220 515 ± 533 0.10 
7 85 ± 87 161 ± 178 0.11 
30 57 ± 61 47 ± 56 0.61 
 
1Data represent the mean ± SD for creatinine, total bilirubin and ALT at different time 
points after surgery. There were no statistically significant differences among the 
groups. Two-tailed, unpaired t test, for each time point. 
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Table 5. Clinical endpoints after surgery for transplanted with Expanded 
Criteria Donors1,2 
 
Day 
Untreated 
n=9 
ALA-treated 
n=10 
p 
PRS  5 (55%) 1 (10%) 0.033 
C
re
at
in
in
e 
(m
g
/d
l)
 
1 1.60 ± 1.44 1.70 ± 0.75 0.846 
2 1.54 ± 1.14 1.35 ± 0.58 0.647 
3 1.32 ± 0.96 1.36 ± 0.95 0.928 
7 1.02 ± 1.09 1.42 ± 1.17 0.448 
30 1.77 ± 1.60 1.32 ± 0.53 0.467 
T
o
ta
l B
ili
ru
b
in
 (
m
g
/d
l)
 
1 5.78 ± 7.27 6.43 ± 5.68 0.829 
2 4.81 ± 7.39 3.70 ± 2.73 0.661 
3 3.96 ± 4.88 3.28 ± 2.72 0.710 
7 2.67 ± 1.99 3.03 ± 3.10 0.768 
30 1.51 ± 0.66 0.94 ± 0.47 0.047 
A
L
T
 (
U
I/L
) 
1 523 ± 274 731 ± 695 0.415 
2 396 ± 283 463 ± 383 0.673 
3 257 ± 196 333 ± 365 0.587 
7 98 ± 109 163 ± 211 0.416 
30 84 ± 76 50 ± 74 0.353 
Dialysis 7 3 (33.3%) 1 ( 10%) 0.213 
Rejections 30 2 (22.2%) 0 (0%) 0.115 
Deaths 180 2 (22.2%) 1  (10 %) 0.466 
 
1Data represent the mean ± SD for creatinine, total bilirubin and ALT at different time 
points after surgery. Unpaired t test, two-tailed, was used.  
2Data represent number of patients that suffered PRS, rejection at 30 days after 
transplantation, need of dialysis during the first week, number of death patients at 6th 
month after transplantation. Chi-square test, two-tailed was used. 
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